ArticleBritish journal of cancer2003
Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer.
Article in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta-analysis.Cancer medicine · 2019Pooled it
- Cyclin D2 - a potential biomarker in uterine corpus endometrial carcinoma through methylation chip and bioinformatic analysis.Frontiers in oncology · 2025Article
- A Necessary Role for Cyclin D2 Induction During Colon Cancer Progression Mediated by L1.Cells · 2024Article
- D-Type Cyclins in Development and Disease.Genes · 2023Review
- Value of Plasma Methylated SFRP2 in Prognosis of Gastric Cancer.Digestive diseases and sciences · 2021Article
- Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Cyclin D degradation by E3 ligases in cancer progression and treatment.Seminars in cancer biology · 2020Review
- Sulforaphane Decrease of SERTAD1 Expression Triggers G1/S Arrest in Breast Cancer Cells.Journal of medicinal food · 2019Article
- Clinical significance and biological roles of cyclins in gastric cancer.OncoTargets and therapy · 2018Article
- Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer.Oncology letters · 2017Article
- Article
- Article
- Article
- Bile acids down-regulate caveolin-1 in esophageal epithelial cells through sterol responsive element-binding protein.Molecular endocrinology (Baltimore, Md.) · 2012Article
- Promoter de-methylation of cyclin D2 by sulforaphane in prostate cancer cells.Clinical epigenetics · 2011Article
- Establishment of a new human osteosarcoma cell line, UTOS-1: cytogenetic characterization by array comparative genomic hybridization.Journal of experimental & clinical cancer research : CR · 2009Article
- Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer.British journal of cancer · 2007Article
- Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer.Cancer science · 2007Article
- Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.Journal of molecular medicine (Berlin, Germany) · 2006Article
- Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas.British journal of cancer · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expression of cyclin D2 is absent in 30-70% of gastric cancers. We investigated the role of promoter hypermethylation in the transcriptional silencing of cyclin D2 in five gastric cell lines and 47 primary gastric carcinomas. CpG island methylation status of the cyclin D2 gene was studied by methylation-specific polymerase chain reaction and bisulphite sequencing. RNA and protein expression was analysed by reverse transcription-PCR and Western blot, respectively. Dense methylation of cyclin D2 was detected in three cell lines (KATOIII, AGS and NCI-N87), which also lacked cyclin D2 mRNA and protein expression. Bisulphite DNA sequencing revealed that loss of cyclin D2 expression was closely associated with the density of methylation in the promoter region. Treatment with DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, restored the cyclin D2 expression level in methylated gastric cells. Among the 47 primary gastric cancers, cyclin D2 hypermethylation was detected in 23 (48.9%) cases. None of the 23 normal gastric biopsies from noncancer patients showed hypermethylation. Hypermethylation was associated with loss of mRNA (P&<0.001) and protein (P=0.006) expressions. Our study showed that cyclin D2 hypermethylation is associated with loss of cyclin D2 expression in a subset of gastric cancers, which may suggest an alternative gastric carcinogenesis pathway in the absence of cyclin D2 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.